Unassociated Document
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION 
WASHINGTON, D.C. 20549 


FORM 8-K 


CURRENT REPORT 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 
 
Date of Report (Date of earliest event reported): September 17, 2007

 
Targeted Genetics Corporation 
(Exact name of registrant as specified in its charter)

 
Washington
 
0-23930
 
91-1549568
(State or other jurisdiction
of incorporation)
 
(Commission File
Number)
 
(IRS Employer
Identification No.)

1100 Olive Way, Suite 100, Seattle, Washington
 
98101
(Address of principal executive offices)
 
(Zip Code)

Registrant’s telephone number, including area code
 
(206) 623-7612

Not Applicable
(Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
 
 


Item 8.01 Other Events.

On September 17, 2007, Targeted Genetics Corporation, or the Company, announced the results of the public hearing conducted by the National Institutes of Health (NIH) Recombinant DNA Advisory Committee, which reviewed the serious adverse event reported by the Company surrounding the death of a patient participating in the Company’s Phase I/II trial of tgAAC94 for inflammatory arthritis.

A copy of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits. 

(d) Exhibits:
 
 
 
99.1
 
Press Release of Targeted Genetics Corporation dated September 17, 2007


 
 
 


SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
TARGETED GENETICS CORPORATION
 
 
 
 
 
 
 
By:  
/s/ H. STEWART PARKER
 
 
H. Stewart Parker
 
 
President and Chief Executive Officer
 
Dated: September 17, 2007
 

 
 
 
 
 
INDEX TO EXHIBITS
 

 
 
 
99.1
 
Press Release of Targeted Genetics Corporation dated September 17, 2007